This report provides an overview of the evidence regarding the impact of COVID-19 and related restrictions on intimate partner violence and child maltreatment. The report also includes information on risk factors for violence, access to support for those at risk, and measures to mitigate the risk of intimate partner violence and child maltreatment during this […]
Tocilizumab and sarilumab are classified as humanized monoclonal antibodies against the interleukin-6 receptor and are used in rheumatology. CADTH has conducted a Technology Review on tocilizumab and sarilumab for their potential use in managing COVID-19. Link to Report Tocilizumab and Sarilumab: Evidence Review and Appraisal (updated February 25, 2021)
REGN-COV2 combines 2 virus-neutralizing monoclonal antibodies that are used against SARS-CoV-2: casirivimab and imdevimab (CAS-IMD). The CADTH Technology Review evaluated a published interim analysis of a randomized controlled trial of 2 different doses of CAS-IMD in 275 ambulatory adult patients with confirmed SARS-CoV-2 infection. Link to Report Casirivimab-Imdevimab for COVID-19: Evidence Review and Appraisal